Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC

Key Points

• Seven Fleet Capital Management acquired 4.35 million Century Therapeutics shares worth approximately $9.8 million, making IPSC its fourth-largest holding and representing a 2.41% stake.
• Institutional ownership stands at 50.20%, with several firms—including AQR Capital, Goldman Sachs and Acadian Asset Management—also increasing their positions.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and a $4.75 target price, while IPSC recently traded at $2.02 after reporting a better-than-expected quarterly loss.

Seven Fleet Capital Management LP purchased a new position in Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,347,826 shares of the company's stock, valued at approximately $9,826,000. Century Therapeutics comprises approximately 3.1% of Seven Fleet Capital Management LP's investment portfolio, making the stock its 4th largest position. Seven Fleet Capital Management LP owned 2.41% of Century Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IPSC. Bank of America Corp DE increased its holdings in Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock valued at $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after buying an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock worth $86,000 after buying an additional 38,052 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Century Therapeutics by 101.2% during the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock worth $133,000 after buying an additional 142,953 shares during the period. Finally, Prudential Financial Inc. acquired a new position in shares of Century Therapeutics during the 2nd quarter worth about $25,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IPSC. Mizuho assumed coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Century Therapeutics in a report on Thursday, July 2nd. HC Wainwright upped their target price on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Century Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Century Therapeutics has an average rating of "Hold" and a consensus target price of $4.75.

Century Therapeutics Price Performance

NASDAQ IPSC opened at $2.02 on Friday. The firm has a market cap of $364.31 million, a P/E ratio of -1.77 and a beta of 1.55. The stock's 50-day moving average is $2.25 and its 200-day moving average is $2.23. Century Therapeutics, Inc. has a one year low of $0.44 and a one year high of $3.04.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. Equities analysts anticipate that Century Therapeutics, Inc. will post -0.43 EPS for the current year.

Century Therapeutics Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

Want to see what other hedge funds are holding IPSC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.